Obiettivo
While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (cervical smear) and availability of a test for the causal agent (human papilloma virus); together these enable identification of high risk individuals and interventions to prevent infection or halt progression to invasive cancer.
Our consortium has developed an exciting opportunity to utilise clinically abundant cervical cells in tandem with a multi-omics enabled (genome, epigenome, metagenome) analysis pipeline to understand an individual’s risk of developing a female specific cancer and to direct a personalised screening and prevention strategy. Cervical cells – currently collected within cervical cancer screening – provide an ideal window into other female specific cancers because they are (i) an excellent non-invasive source of high quality DNA, (ii) provide a readout for environmental exposure, (iii) are part of the Müllerian tract and (iv) are hormone sensitive, recording (via the epigenome) various hormonal conditions over a lifetime that trigger cancer development. The FORECEE project is aligned with the novel concept of “P4 Medicine” (predictive, preventive, personalized, and participatory): it aims to translate the risk prediction tool’s output into personalised recommendations for screening and prevention of female cancers.
Our consortium comprises a multi-disciplinary team of experts in clinical oncology, risk-benefit communication, omics technologies, decision analysis, health economics and public health. We will examine the effectiveness of the proposed cervical cell omics analysis method and investigate the legal, social, ethical and behavioural issues related to implementation of the risk prediction tool, through direct interaction with stakeholder groups, to ensure its rapid translation into clinical practice across Europe.
Campo scientifico
- medical and health scienceshealth sciencespublic health
- medical and health sciencesbasic medicinephysiologycytology
- medical and health sciencesclinical medicineoncologycervical cancer
- social scienceseconomics and businesseconomicshealth economics
- medical and health scienceshealth sciencesinfectious diseasesDNA viruses
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-PHC-2014-two-stage
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
WC1E 6BT London
Regno Unito
Mostra sulla mappa
Partecipanti (14)
17177 Stockholm
Mostra sulla mappa
116 36 Praha 1
Mostra sulla mappa
5021 Bergen
Mostra sulla mappa
20121 Milano
Mostra sulla mappa
SO16 6YD Southampton
Mostra sulla mappa
Soggetto giuridico diverso da un subappaltatore che è affiliato o legalmente collegato a un partecipante. Il soggetto svolge le attività secondo le condizioni stabilite nell’accordo di sovvenzione, fornisce beni o servizi per l’azione, ma non ha sottoscritto l’accordo di sovvenzione. Una terza parte rispetta le regole applicabili al suo partecipante correlato ai sensi dell’accordo di sovvenzione per quanto riguarda l’ammissibilità dei costi e il controllo delle spese.
SO17 1BJ Southampton
Mostra sulla mappa
80539 Muenchen
Mostra sulla mappa
WC1E 7HT London
Mostra sulla mappa
Partecipazione conclusa
CB2 1TN Cambridge
Mostra sulla mappa
3015 GD Rotterdam
Mostra sulla mappa
6020 INNSBRUCK
Mostra sulla mappa
80539 Munchen
Mostra sulla mappa
Partecipazione conclusa
LN1 1XW Lincoln
Mostra sulla mappa
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
78467 Konstanz
Mostra sulla mappa